AMICUS THERAPEUTICS, INC. — Director's Dealing 2023

Feb 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-02-01

Reporting Person: Campbell Bradley L (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-01	Common Stock	M	11700	$2.45	Acquired	865129	Direct
2023-02-01	Common Stock	S	20000	$12.9754	Disposed	845129	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-01	Stock Options (right to buy)	$2.45	M	11700	Disposed	2024-01-03	Common Stock (11700)	Direct

Footnotes

F1: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.80 to $13.28 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of the options were fully vested and exercisable as of the transaction date.